CelLBxHealth PLC - Preliminary Results
For Immediate Release |
|

CelLBxHealth plc
("CelLBxHealth" or "the Company")
Preliminary Results for the year ended
Strategic repositioning with strengthened leadership and board, substantially reduced cost base and commercial focus on partnership-driven growth
CelLBxHealth Executive Chairman,
"2025 was a year of significant transition for the Company with decisive action taken to strengthen leadership, substantially reduce the cost base and reposition the business around a focused, partnership-driven strategy. We believe these changes have established a stronger operational and financial foundation for the future. With a streamlined organisation, strengthened governance framework and growing strategic engagement from leading diagnostics and pharmaceutical partners, we are focused on disciplined execution and converting our commercial pipeline into sustainable revenue growth."
Financial Highlights
· Total revenue of
Revenue comprised of:
o product and services revenue of
o biopharma services revenue of
· Gross profit margins held at 62% (2024: 62%)
· Operating loss of
· Loss after tax of
· Successful fundraise completed in
· Cash and cash equivalents of
· Restructuring project nearly completed, reducing annualised operating cash costs to approximately
Operational Highlights
· Business strategically repositioned from a research-focused organisation to a commercially driven, partner-led and capital-efficient operating model
· Corporate rebrand to CelLBxHealth completed to reflect the Company's revised strategic direction
· New leadership and governance structure implemented:
o
o strengthening of the Board adding three Non-executive Directors
· Operational restructuring completed, resulting in annualised cost savings of approximately
o 60% reduction in headcount
o consolidation into a single operating location
o renegotiation of supplier and service contracts
· Strategic collaborations progressed with QIAGEN, Roche Diagnostics, Illumina and Myriad
Post closing events
· Master Service Agreement with AstraZeneca announced
· Collaboration agreement with AdventHealth for two studies monitoring CTCs to improve cancer care
· Research collaboration with The Royal Marsden NHS Foundation Trust on novel CTC clinical study in advanced non-small cell lung cancer
· Sub-lease on US facility effective
Outlook
· The Board believes the actions taken in Q4 2025 have established a leaner, more focused and commercially aligned platform for future growth
· Further operational efficiencies implemented during Q1 2026, reducing headcount from 44 to 39 employees and further lowering the ongoing cost base
· The qualified commercial pipeline continues to build, supported by strategic collaborations and increasing engagement from pharmaceutical and diagnostic partners. The pipeline has grown by 22% over the last quarter, with significant interest across pharma and biotech
· FY 2026 revenues are expected to be at least
· With a much-reduced cost base and more efficient operating model, the Company has a cash runway into Q2 2027
· The Company remains focused on disciplined execution, progression of validation programmes, expansion of strategic partnerships and conversion of commercial opportunities into sustainable revenues
Investor presentation
Investors can sign up to Investor Meet Company for free and add to meet CelLBxHealth plc via: https://www.investormeetcompany.com/cellbxhealth-plc/register
The audited statutory Financial Statements for the year ended
For further information:
|
CelLBxHealth plc |
via Walbrook PR |
|
|
|
|
Cavendish (NOMAD and Broker) |
+44 (0) 20 7220 0500 |
|
|
|
|
Walbrook PR (Investor and Media Relations) |
Tel: +44 (0)20 7933 8780 or CelLBx@walbrookpr.com Mob: +44 (0)7980 541 893 / +44 (0)7407 804 654 |
Notes for editors
About CelLBxHealth plc
CelLBxHealth plc is a CTC intelligence company specialising in innovative circulating tumour cell (CTC) solutions for use in research, drug development and clinical oncology. Its patent-protected Parsortix® platform harvests CTCs from blood and can be integrated with existing laboratory instruments for comprehensive downstream analysis - including whole-cell imaging, proteomic profiling and full genomic workflows.
Commercial focus spans three revenue streams - Product Sales of the Parsortix platform and consumables through CRO and clinical lab partnerships, Laboratory Services including clinical trial support and assay development delivered from a GCLP-compliant
For more information, visit https://cellbxhealth.com/.
Executive Chairman's letter to Shareholders
Dear Shareholders,
I have taken decisive action to address the challenges of 2025 through the appointment of new leadership and Non-executive Directors of the Board. Together, we expect to drive the Company to consistent and sustainable growth across our product portfolio. Our focus is firmly on disciplined execution across all operational areas and on building long-term value for our shareholders. We remain confident in the clinical and economic value of our CTC platform and its associated consumables.
In
Peter brings more than 25 years of leadership experience in oncology drug and diagnostics development, having held senior executive roles in both private and publicly listed organisations. His previous positions include Chief Executive Officer at SAGA Diagnostics, Chief Business Officer at Inivata, Vice President of Biopharma Business Development at Guardant Health, and Head of Diagnostics at GSK. Peter's extensive industry experience, combined with his personal integrity and leadership capabilities, make him ideally suited to lead the Company and maximise value for all stakeholders, including patients, customers and shareholders.
In
Whilst I was disappointed with the Company's commercial performance under the previous executive team, I remain firmly convinced of the quality, market opportunity and growth potential of our CTC platform and related services. Under the new leadership framework, the Company was rebranded as CelLBxHealth in
Historically, the Company intended to develop and commercialise its own downstream analysis platforms, imaging solutions and molecular reagent kits. However, numerous scientific studies have already demonstrated the value of CTCs for improved therapy selection and disease monitoring of cancer patients. My view is therefore that the CTC platform should be integrated with well-established and widely adopted downstream analysis platforms, in vitro diagnostic (IVD) kits and reagent systems to accelerate adoption across research institutions, clinical centres and contract research organisations.
A central element of the revised business model is the development of strategic collaborations with global diagnostic companies. Encouraging progress has already been made, with collaborations established with QIAGEN, Roche Diagnostics, Myriad Genetics and Illumina to validate CTC-based workflows that leverage existing tissue and circulating tumour DNA (ctDNA) tests on platforms with a substantial installed base. These collaborations are expected to increase commercial adoption of the Parsortix® platform and open additional revenue opportunities across a broader customer base, including contract research organisations and clinical laboratories.
The initial 2025 revenue forecast was
In
As previously announced, the Company has implemented substantial cost-reduction initiatives, including a significant organisational restructuring and the renegotiation of third-party service contracts. Collectively, these measures are expected to deliver
At
The Board remains positive about the outlook for the coming year and believes the Company is on track to continue reshaping the business, implement further cost efficiencies and drive adoption of the CTC platform to accelerate revenue growth.
I would like to conclude by thanking our employees for their hard work and commitment, our partners and scientific advisers for their continued support, as well as the clinicians and patients who contribute to our mission. Finally, I thank our shareholders for their continued confidence. The path ahead will require focus and disciplined execution as we continue our mission to bring our CTC testing solutions to clinicians and patients around the world.
Yours sincerely,
Executive Chairman of the Board
Chief Executive's Statement
The year ended
In
The revised strategy is centred on driving revenue through product sales, laboratory services and supporting the development of laboratory developed tests (LDTs), enabled by the expansion of strategic partnerships with established diagnostics companies to integrate the Company's CTC platform alongside widely adopted downstream platforms, rather than pursuing a standalone development pathway. The Board believes this approach will accelerate commercial adoption by leveraging established laboratory infrastructure and clinical workflows.
During the reporting period, the Company made encouraging progress in establishing collaborations with leading global diagnostics organisations including Myriad, Roche and QIAGEN, supporting the validation of CTC-based workflows and enhancing the potential for broader market adoption across research institutions, contract research organisations (CROs) and clinical laboratories.
In parallel with the strategic repositioning, the Company implemented a substantial operational restructuring to align its cost base and organisational structure with its revised commercial focus. This included a 60% reduction in headcount, consolidation of operations into a single site at
The Company reported revenue of
In
The Board and I recognise that the successful execution of the revised strategy is subject to risks and uncertainties, including the pace of market adoption, dependence on strategic partners, clinical validation outcomes and the evolving regulatory environment. These risks are actively managed through the Company's established risk management framework, with a focus on diversification of revenue streams, collaboration with established industry partners and maintaining financial discipline.
Outlook
Looking ahead, we believe that the actions taken during 2025 and the first quarter of 2026 have established a focused, efficient and commercially aligned platform for growth. During Q1 2026, management prioritised the organisational restructuring required, delivering further cost reductions and operational efficiencies while maintaining focus on commercial execution.
The CTC market is projected to be the fastest growing area of the liquid biopsy market, increasing to
Alongside these operational improvements, the Company has maintained an acute focus on driving commercial progress and revenue growth, including the appointment of a US-based, VP Commercial, in
This is supported by several strategically important commercial and clinical collaborations that further validate the growing adoption and utility of the Parsortix platform. These include a research collaboration with The Royal Marsden NHS Foundation Trust in advanced non-small cell lung cancer, focused on evaluating the complementary role of CTC-DNA profiling in patients where ctDNA testing is uninformative. The Company has also announced a collaboration with AdventHealth, one of the largest faith-based healthcare systems in
The Company's priorities for the remainder of 2026 remain centred on disciplined execution of its partner-led strategy, progression of validation programmes and conversion of strategic collaborations into sustainable revenue streams. The Board and I remain confident in the underlying potential of the Company's technology and its ability to deliver long-term value for shareholders, while recognising that consistent delivery against commercial objectives will remain critical in the period ahead.
Chief Executive
CELLBXHEALTH PLC
CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME
FOR THE YEAR ENDED
|
|
2025 |
2024 |
||
|
|
Note |
£'000 |
|
£'000 |
|
Revenue |
|
1,351 |
|
2,862 |
|
Cost of sales |
|
(519) |
|
(1,083) |
|
Gross profit |
|
832 |
|
1,779 |
|
Other operating income |
5 |
956 |
|
- |
|
Operating costs |
|
(21,037) |
|
(16,875) |
|
Operating loss |
|
(19,249) |
|
(15,096) |
|
Finance income |
|
126 |
|
396 |
|
Finance costs |
|
(285) |
|
(329) |
|
Loss before tax |
|
(19,408) |
|
(15,029) |
|
Tax (charge)/credit |
5 |
(101) |
|
804 |
|
Loss for the year |
|
(19,509) |
|
(14,225) |
|
Other comprehensive income/(loss) |
|
|
|
|
|
Items that may be subsequently reclassified to profit or loss: |
|
|||
|
Exchange differences on translating foreign operations |
1,625 |
|
(376) |
|
|
Other comprehensive income/(loss) |
|
1,625 |
|
(376) |
|
Total comprehensive loss for the year |
|
(17,884) |
|
(14,601) |
|
|
|
|
|
|
|
Loss per share attributable to owners of the parent Basic and Diluted (pence per share) |
6 |
(5.51) |
|
(4.82) |
|
All activity arose from continuing operations.
|
|
|
|
|
CELLBXHEALTH PLC
CONSOLIDATED STATEMENT OF FINANCIAL POSITION
AS AT
|
|
|
|
2025 |
|
2024 |
|
|
|
Note |
|
|
£'000 |
|
£'000 |
|
Assets |
|
|
|
|
|
|
|
Non-current assets |
|
|
|
|
|
|
|
Intangible assets |
|
|
|
390 |
|
2,648 |
|
Property, plant and equipment |
|
|
|
1,065 |
|
2,475 |
|
Right-of-use assets |
|
|
|
740 |
|
3,927 |
|
Total non-current assets |
|
|
|
2,195 |
|
9,050 |
|
|
|
|
|
|
|
|
|
Current assets |
|
|
|
|
|
|
|
Inventories |
|
|
|
1,296 |
|
1,579 |
|
Trade and other receivables |
|
|
|
1,744 |
|
2,087 |
|
Taxation |
|
|
|
- |
|
2,317 |
|
Cash and cash equivalents |
|
|
|
7,349 |
|
10,425 |
|
Total current assets |
` |
|
|
10,389 |
|
16,408 |
|
|
|
|
|
|
|
|
|
Total assets |
|
|
|
12,584 |
|
25,458 |
|
Liabilities |
|
|
|
|
|
|
|
Non-current liabilities |
|
|
|
|
|
|
|
Lease liabilities |
|
|
|
(1,000) |
|
(3,348) |
|
Provisions |
|
|
|
(618) |
|
(362) |
|
Trade and other payables |
|
|
|
- |
|
(49) |
|
Total non-current liabilities |
|
|
|
(1,618) |
|
(3,759) |
|
Current liabilities |
|
|
|
|
|
|
|
Lease liabilities |
|
|
|
(817) |
|
(862) |
|
Provisions |
|
|
|
(434) |
|
(179) |
|
Corporation tax payable |
|
|
|
(181) |
|
- |
|
Trade and other payables |
|
|
|
(2,338) |
|
(2,217) |
|
Total current liabilities |
|
|
|
(3,770) |
|
(3,258) |
|
|
|
|
|
|
|
|
|
Total liabilities |
|
|
|
(5,388) |
|
(7,017) |
|
Net assets |
|
|
|
7,196 |
|
18,441 |
|
Equity |
|
|
|
|
|
|
|
Share capital |
7 |
|
|
32,673 |
|
32,264 |
|
Share premium |
|
|
|
125,299 |
|
118,362 |
|
Share-based payments reserve |
|
|
|
2,582 |
|
3,754 |
|
Other reserve |
|
|
|
2,553 |
|
2,553 |
|
Translation reserve |
|
|
|
(3,620) |
|
(5,245) |
|
Accumulated losses |
|
|
|
(152,157) |
|
(133,145) |
|
ESOT shares |
|
|
|
(134) |
|
(102) |
|
Total equity |
|
|
|
7,196 |
|
18,441 |
CELLBXHEALTH PLC
CONSOLIDATED STATEMENT OF CASH FLOWS
FOR THE YEAR ENDED
|
2025 £'000 |
2024 £'000 |
||
|
Operating activities |
|
|
|
|
Profit/(loss) before tax |
(19,408) |
|
(15,029) |
|
Adjustments for: |
|
|
|
|
Depreciation and impairment of property, plant and equipment |
1,588 |
|
813 |
|
Depreciation and impairment of right-of-use assets |
1,756 |
|
751 |
|
Loss on disposal of property, plant and equipment |
56 |
|
11 |
|
Gain on reassessment of lease term on right-of-use assets |
(54) |
|
- |
|
Amortisation and impairment of intangible assets |
2,279 |
|
134 |
|
Share-based payment charge/(credit) |
(752) |
|
1,453 |
|
Exchange differences |
1,634 |
|
(382) |
|
R&D tax credit income |
(956) |
|
- |
|
Net finance (income)/costs |
159 |
|
(67) |
|
Operating cash flows before movements in working capital |
(13,698) |
|
(12,316) |
|
(Increase)/decrease in inventories |
206 |
|
153 |
|
(Increase)/decrease in trade and other receivables |
1,238 |
|
(304) |
|
Increase/(decrease) in trade and other payables |
79 |
|
(585) |
|
Increase/(decrease) in provisions |
515 |
|
(396) |
|
Operating cash flows |
(11,660) |
|
(13,448) |
|
Research and development tax credits received |
2,397 |
|
- |
|
Net cash from/(used in) operating activities |
(9,263) |
|
(13,448) |
|
Investing activities |
|
|
|
|
Purchase of property, plant and equipment |
(216) |
|
(396) |
|
Initial direct costs capitalised into right-of-use asset |
- |
|
(15) |
|
Purchase of intangible assets |
(33) |
|
(33) |
|
Interest received |
126 |
|
396 |
|
Net cash from/(used in) investing activities |
(123) |
|
(48) |
|
Financing activities |
|
|
|
|
Net proceeds from issue of share capital - placing |
7,623 |
|
8,631 |
|
Shares acquired by ESOT |
(32) |
|
- |
|
Principal elements of lease payments |
(1,037) |
|
(805) |
|
Interest elements of lease payments |
(263) |
|
(158) |
|
Net cash from/(used in) financing activities |
6,291 |
|
7,668 |
|
Net increase/(decrease) in cash and cash equivalents |
(3,095) |
|
(5,828) |
|
Cash and cash equivalents at 1 January |
10,425 |
|
16,218 |
|
Effect of exchange rate fluctuations |
19 |
|
35 |
|
Cash and cash equivalents at 31 December |
7,349 |
|
10,425 |
CELLBXHEALTH PLC
CONSOLIDATED STATEMENT OF CHANGES IN EQUITY
FOR THE YEAR ENDED
|
|
------------------------------------------ Equity attributable to owners of the parent ---------------------------------------------- |
|
|
Share |
Share |
Share-based payments |
Other |
Translation |
Accumulated |
ESOT |
Total |
|
|
capital |
premium |
reserve |
reserve |
reserve |
losses |
shares |
equity |
|
|
£'000 |
£'000 |
£'000 |
£'000 |
£'000 |
£'000 |
£'000 |
£'000 |
|
At |
26,058 |
115,918 |
5,709 |
2,553 |
(4,869) |
(122,328) |
(102) |
22,939 |
|
For the year to |
|
|
|
|
|
|
|
|
|
Consolidated loss |
|
|
|
|
|
(14,225) |
|
(14,225) |
|
Other comprehensive income/(loss) |
|
|
|
|
(376) |
|
|
(376) |
|
Total comprehensive income/(loss) |
|
|
|
|
(376) |
(14,225) |
|
(14,601) |
|
Transactions with owners in their capacity as owners: |
|
|
|
|
|
|
|
|
|
Issue of shares (net of costs) |
6,206 |
2,444 |
|
|
|
|
|
8,650 |
|
Share-based payment expense |
|
|
1,453 |
|
|
|
|
1,453 |
|
Released on forfeiture/lapse |
|
|
(3,408) |
|
|
3,408 |
|
- |
|
Total transactions with owners
|
6,206
|
2,444
|
(1,955)
|
-
|
-
|
3,408
|
-
|
10,103
|
|
At |
32,264 |
118,362 |
3,754 |
2,553 |
(5,245) |
(133,145) |
(102) |
18,441 |
|
|
|
|
|
|
|
|
|
|
|
For the year to |
|
|
|
|
|
|
|
|
|
Consolidated loss |
|
|
|
|
|
(19,509) |
|
(19,509) |
|
Other comprehensive income/(loss) |
|
|
|
|
1,625 |
|
|
1,625 |
|
Total comprehensive income/(loss) |
|
|
|
|
1,625 |
(19,509) |
|
(17,884) |
|
Transactions with owners in their capacity as owners: |
|
|
|
|
|
|
|
|
|
Issue of shares (net of costs) |
409 |
7,014 |
|
|
|
|
|
7,423 |
|
Shares acquired by ESOT |
|
|
|
|
|
|
(32) |
(32) |
|
Share-based payment credit |
|
|
(752) |
|
|
|
|
(752) |
|
Equity-settled share-based payment - broker warrants |
|
(77) |
77 |
|
|
|
|
- |
|
Released on forfeiture/lapse |
|
|
(497) |
|
|
497 |
|
- |
|
Total transactions with owners
|
409
|
6,937
|
(1,172)
|
-
|
-
|
497
|
(32)
|
6,639
|
|
At |
32,673 |
125,299 |
2,582 |
2,553 |
(3,620) |
(152,157) |
(134) |
7,196 |
CELLBXHEALTH PLC
NOTES TO THE PRELIMINARY ANNOUNCEMENT
FOR THE YEAR ENDED
1 Preliminary announcement
The preliminary results for the year ended
The preliminary announcement set out above does not constitute CelLBxHealth plc's statutory Financial Statements for the years ended
The Financial Statements for the year ended
The auditor's report on the Consolidated Financial Statements for the years ended
The accounting policies used for the year ended
2 Compliance with accounting standards
The financial information included in this preliminary announcement has been prepared in accordance with the recognition and measurement requirements of
Accounting standards adopted in the year
No new accounting standards that have become effective and adopted in the year have had a significant effect on the Group's Financial Statements.
Accounting standards issued but not yet effective
At the date of authorisation of these Financial Statements, a number of new standards, amendments and interpretations had been issued but were not yet effective and have not been applied in these Financial Statements.
The Directors do not expect the adoption of the amendments to IFRS 9 and IFRS 7, or the Annual Improvements to IFRS Accounting Standards, to have a material impact on the Group's Financial Statements.
The Group has not yet completed its assessment of IFRS 18 Presentation and Disclosure in Financial Statements, which is effective for annual periods beginning on or after
3 Going concern
The Financial Statements have been prepared on a going concern basis. In adopting this basis, the Directors have assessed the Group's ability to continue as a going concern for a period of at least 12 months from the date of approval of these Financial Statements, taking into account all available information.
The Group's business activities, together with the factors likely to affect its future development, performance and financial position, are set out in the Executive Chairman's letter and the Chief Executive's Statement.
At
The Directors have prepared a detailed monthly forecast to
During late 2025 and early 2026, the Directors took the action to right-size the cost base, including headcount reductions expected to deliver in excess of
The Directors have identified several near-term commercial opportunities that support the funding outlook, including a collaboration with AdventHealth one of the largest US private healthcare providers and executing a Master Services Agreement with AstraZeneca, a top-ten global pharmaceutical company. The Group's lung-cancer development programme with the NHS presents the opportunity to bring CTCs into clinical practice reflexing patients with uninformative ctDNA results to CTCs to identify actionable alterations providing eligibility for a range of effective therapies. A successful programme would represent a potential source of future revenue, although the timing of any associated income remains outside the Group's direct control and has not been assumed in the base case forecast.
The Directors believe several potential funding sources are available to the Group, including revenues, commercial milestones, licensing income, and debt or equity financing. However, based on current forecasts, the Group will require additional funding to continue operations beyond H1 2027. There can be no certainty that such funding will be obtained on acceptable terms, or at all.
The Group's forecasts are dependent upon the successful and timely conversion of a number of significant commercial opportunities into revenue, the timing and extent of which remain uncertain. A significant proportion of forecast revenues is concentrated within a relatively small number of opportunities and customers, and many pipeline opportunities remain at proposal stage. There can be no certainty that forecast revenues will be achieved in line with management's expectations. These conditions, together with the requirement for additional funding beyond H1 2027, represent a material uncertainty that may cast significant doubt on the Group's ability to continue as a going concern. Notwithstanding this, the Directors have a reasonable expectation that the Group will be able to secure the necessary funding and meet its liabilities as they fall due. As a result, the Financial Statements continue to be prepared on a going concern basis and do not include any adjustments that would result if the Group were unable to continue as a going concern.
4 Critical accounting estimates and judgements
The preparation of the Financial Statements requires management to make judgements and estimates that affect the application of accounting policies and the reported amounts of assets, liabilities, income and expenses. Actual results may differ from these estimates. The key areas involving significant judgement during the year are set out below.
Impairment of goodwill
Significant judgement was exercised in assessing the recoverability of goodwill at
Leases - lease term and break option assessment
Significant judgement is required in determining lease terms under IFRS 16, including whether break options are reasonably certain to be exercised. During the year, the Group reassessed the term of its
Contingent liabilities
Management has exercised judgement in assessing the likelihood of future outflows relating to legal proceedings and potential claims. Based on the information available at the reporting date, no provision has been recognised as an outflow of economic benefits is considered possible but not probable.
5 Tax
The Group undertakes research and development activities. During the year the Group recognised
6 Loss per share attributable to owners of the parent
Basic and diluted loss per share is calculated by dividing the loss attributable to owners of the parent of
As the Group reported a loss for both 2025 and 2024, potentially dilutive share options have not been included in the calculation of diluted loss per share as they are anti-dilutive. As a result, diluted loss per share is equal to basic loss per share.
The weighted average number of ordinary shares used in the calculation was 353,834,856 (2024: 294,932,245).
7 Share capital
At
During the year, the Company undertook a share capital reorganisation whereby each ordinary share of
Following the reorganisation, the Company issued 816,760,990 new ordinary shares through a placing and retail offer, raising gross proceeds of
8 Shareholder communications
Copies of this announcement are posted on the Company's website www.CelLBxHealth.com.
The Annual General Meeting (AGM) of the Company will be held at
The Notice of Annual General Meeting is available on the Company's website at https://cellbxhealth.com/information-for-investors-cellbxhealth-plc/financial-reports/#general-meeting-documentation and has been distributed to shareholders in accordance with applicable requirements.
The audited statutory Financial Statements for the year ended
This preliminary announcement was approved by the Board of Directors on
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Proactive Investors is a publisher of financial news and information. No content in this record, or published on the Proactive Investors website (the "Site"), constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. No content is tailored to any specific person's needs, objectives, or financial situation.
Proactive Investors is not a registered investment adviser or broker-dealer and does not provide personalized investment advice. Nothing in this record constitutes investment advice or a recommendation to buy, hold, or sell any security. None of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, or suitability of any particular security, portfolio, transaction, or investment strategy. Any decision to buy, sell, or hold a security should be made only after consulting an appropriately qualified, licensed financial adviser and reading all relevant offering documentation.
This record, and any record we publish by or on behalf of our clients, should not be construed as an offer or solicitation to buy or sell any product or security. Our content is independent financial journalism, produced in a neutral, objective style with full source attribution.
In accordance with the Federal Trade Commission's guidelines on material connections, Proactive Investors discloses the following: we may receive cash or, in some cases, equity compensation from companies whose news is distributed through our platform. This compensation is for news distribution and media services, not for editorial content or coverage decisions. Where Proactive Investors has a commercial relationship with a company covered in this record, that relationship is disclosed within the article. Any such relationship does not determine, influence, or shape the editorial content produced. Where we receive equity compensation, such securities are held independently by a third-party broker and sold at the broker's discretion.
The Site may contain opinions from time to time regarding securities mentioned in other products, including company-related products, and those opinions may differ from those obtained through another Proactive Investors product. Opinions and commentary reflect the views of the named author at the time of writing and are subject to change without notice.
Price and other data is supplied by sources believed to be reliable. Any calculations are made using such data. Neither the data nor the calculations are guaranteed by those sources, by Proactive Investors, by the information providers, or by any other person or entity, and may not be complete or accurate.
From time to time, reference may be made in our marketing materials to previously published articles or opinions. Such references may be selective, may reference only a portion of an article, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.
FOR OUR FULL DISCLAIMER CLICK HERE